Academic Journal
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney
| العنوان: | Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney |
|---|---|
| المؤلفون: | Giudice, Giulia Claire, Maruzzo, Marco, Verzoni, Elena, Procopio, Giuseppe, Bimbatti, Davide, Sepe, Pierangela, Maines, Francesca, Grillone, Francesco, Cavo, Alessia, Santoni, Matteo, Cordua, Nadia, Pecoraro, Giovanna, Prati, Veronica, Napoli, Marilena Di, Ollari, Eli, Caruso, Giuseppe, Simoni, Nicola, Campobasso, Davide, Buti, Sebastiano |
| المساهمون: | Giudice, Giulia Claire, Maruzzo, Marco, Verzoni, Elena, Procopio, Giuseppe, Bimbatti, Davide, Sepe, Pierangela, Maines, Francesca, Grillone, Francesco, Cavo, Alessia, Santoni, Matteo, Cordua, Nadia, Pecoraro, Giovanna, Prati, Veronica, Napoli, Marilena Di, Ollari, Eli, Caruso, Giuseppe, Simoni, Nicola, Campobasso, Davide, Buti, Sebastiano |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2024 |
| المجموعة: | Università di Parma: CINECA IRIS |
| مصطلحات موضوعية: | Bellini duct carcinoma, Collecting duct carcinoma, Genitourinary tumor, Rare, Registry |
| الوصف: | Introduction: Rare genitourinary tumors are lacking of randomized and observational data. We aimed to describe the clinical characteristics and outcomes of patients with collecting duct carcinoma (CDC) through the Meet-URO 23/I-RARE database. Materials and methods: We performed a multicentric retrospective-prospective study within the Meet-URO network, enrolling patients from March 2021 (retrospectively up from 2011) until March 2023. The primary objective was to describe the clinical characteristics of patients with CDC, the secondary objectives were to assess the oncological outcomes in terms of relapse-free survival (RFS), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) to treatment. Results: 37 patients with CDC were enrolled. Four patients underwent only surgery, 33 received first-line systemic therapy. Median OS was 22.1 months (95% CI, 8.9-31.9). Median RFS for patients with localized disease at onset (n = 30) was 3.7 months (95% CI, 1.9-12.8), median PFS for first-line treatment was 3.3 months (95% CI, 2.7-9.9), with an ORR of 27%. Female sex and good performance status (PS) were associated with longer PFS (P = .072 and P < .01, respectively) and OS (P = .030 and P = .141, respectively). Conclusions: Patients with CDC had dismal prognosis, with scarce benefit from the available treatments. Female sex and good PS seemed to be associated with better prognosis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:001317818900001; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11381/2994673 |
| DOI: | 10.1016/j.clgc.2024.102186 |
| الاتاحة: | https://hdl.handle.net/11381/2994673 https://doi.org/10.1016/j.clgc.2024.102186 https://www.clinical-genitourinary-cancer.com/article/S1558-7673(24)00157-5/fulltext |
| رقم الانضمام: | edsbas.EED75A71 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.clgc.2024.102186 |
|---|